Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23243863 | 0.85 | GPR88 (0.46) | MAOBCYP2D6KCNH2CACNA1B | |
| SCHEMBL21834303 | 0.83 | MAOB (0.37) | MAOBCYP2D6KCNH2CACNA1B | |
| SCHEMBL21834278 | 0.83 | GPR88 (0.35) | — | |
| SCHEMBL21834279 | 0.82 | MAOB (0.41) | MAOBMAOA | |
| SCHEMBL21834275 | 0.82 | MAOB (0.41) | MAOBMAOA | |
| SCHEMBL21834277 | 0.82 | MAOB (0.41) | MAOBMAOA | |
| SCHEMBL21834315 | 0.81 | MAOB (0.40) | MAOBMAOA | |
| SCHEMBL21834242 | 0.80 | MAOB (0.39) | MAOBCYP2D6KCNH2CACNA1BALOX5 | |
| SCHEMBL21834297 | 0.80 | MAOB (0.39) | MAOBCYP2D6KCNH2CACNA1BALOX5 | |
| SCHEMBL21834345 | 0.76 | CYP2D6 (0.39) | MAOBCYP2D6KCNH2CACNA1BMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034101-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-01-30 | — | — | US | claimed |
| US-12145914-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-11-19 | — | — | US | claimed |
| CN-113272285-B | Oxadiazole-containing compound and pharmaceutical composition containing same | 爱思开生物制药株式会社 | 2024-06-07 | — | — | CN | claimed |
| US-20230150955-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-05-18 | — | — | US | claimed |
| US-11603358-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-03-14 | — | — | US | claimed |
| US-20220024886-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. | 2022-01-27 | — | — | US | claimed |
| CN-113272285-A | Oxadiazole-containing compound and pharmaceutical composition containing the same | 爱思开生物制药株式会社 | 2021-08-17 | — | — | CN | claimed |
| EP-3854788-A1 | COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SK Biopharmaceuticals Co., Ltd. (KR) | 2021-07-28 | — | — | EP | claimed |
| US-11053208-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-07-06 | — | — | US | claimed |
| US-20210115001-A1 | Compound Having Oxadiazole And Pharmaceutical Composition Containing The Same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-04-22 | — | — | US | claimed |
| WO-2020060299-A1 | COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 에스케이바이오팜 주식회사 | 2020-03-26 | — | — | WO | claimed |
| US-20250034101-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-12145914-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-11-19 | — | — | US | disclosed |
| CN-113272285-B | Oxadiazole-containing compound and pharmaceutical composition containing same | 爱思开生物制药株式会社 | 2024-06-07 | — | — | CN | disclosed |
| US-20230150955-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-11053208-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-07-06 | — | — | US | disclosed |
| US-11053208-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-07-06 | — | — | US | disclosed |
| US-20210115001-A1 | Compound Having Oxadiazole And Pharmaceutical Composition Containing The Same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-04-22 | — | — | US | disclosed |
| US-20210115001-A1 | Compound Having Oxadiazole And Pharmaceutical Composition Containing The Same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-04-22 | — | — | US | disclosed |
| WO-2020060299-A1 | COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 에스케이바이오팜 주식회사 | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150955-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OTC, OXA1L, ATP6V1B2 | MAOB 407/4885CYP2D6 23/4885LTB4R 3069/4885 |
| US-20220024886-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OTC, OXA1L, ATP6V1B2 | MAOB 407/4885CYP2D6 23/4885LTB4R 3069/4885 |
| US-20250034101-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OTC, OXA1L, ATP6V1B2 | MAOB 407/4885CYP2D6 23/4885LTB4R 3069/4885 |
| US-11053208-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | OTC, OXA1L, ATP6V1B2 | MAOB 407/4885CYP2D6 23/4885LTB4R 3069/4885 |
| US-20210115001-A1 | Compound Having Oxadiazole And Pharmaceutical Composition Containing The Same | OTC, OXA1L, ATP6V1B2 | MAOB 407/4885CYP2D6 23/4885LTB4R 3069/4885 |
| US-11603358-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | OTC, OXA1L, ATP6V1B2 | MAOB 407/4885CYP2D6 23/4885LTB4R 3069/4885 |
| US-12145914-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | OTC, OXA1L, ATP6V1B2 | MAOB 407/4885CYP2D6 23/4885LTB4R 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.